InterAx Biotech AG announced today that it has entered an agreement with GPCR Therapeutics, a biopharmaceutical company focusing on developing drugs targeting disease-specific GPCR heterodimers.
“The long-standing in-house expertise on the biology of GPCR heteromers and chemokines at InterAx and the cutting-edge approach of GPCR Therapeutics in targeting relevant heteromers in cancer has resulted in an exciting collaboration. Our unique computational approach to characterize specific signaling patterns of relevant GPCR heteromers will help to identify compounds with superior biological properties”, says Maria Waldhoer, CSO at InterAx. “We are also delighted to be working with an uprising biopharmaceutical company in South Korea, as we are for the first time introducing our platform beyond European borders.”
“We are excited to have the opportunity to partner with InterAx to prioritize drug candidates targeting GPCR heteromers. We hope that combining our innovative platform to target cancer-specific GPCR heteromers with InterAx systems biology modeling will ultimately lead to major discoveries that will benefit patients," says Dr. Dong Seung Seen, the CEO of GPCR Therapeutics, Inc.